Top

Published in:

01-06-2015 | Research Article

Relationship Between [¹⁸F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas

Authors: Elena Karavaeva, Robert J. Harris, Kevin Leu, Maryam Shabihkhani, William H. Yong, Whitney B. Pope, Albert Lai, Phioanh L. Nghiemphu, Linda M. Liau, Wei Chen, Johannes Czernin, Timothy F. Cloughesy, Benjamin M. Ellingson

Published in: Molecular Imaging and Biology | Issue 3/2015

Abstract

Purpose

Diffusion magnetic resonance imaging (MRI) and 6-[¹⁸F]fluoro-l-dopa ([¹⁸F]FDOPA) positron emission tomography (PET) are used to interrogate malignant tumor microenvironment. It remains unclear whether there is a relationship between [¹⁸F]FDOPA uptake, diffusion MRI estimates of apparent diffusion coefficient (ADC), and mitotic activity in the context of recurrent malignant gliomas, where the tumor may be confounded by the effects of therapy. The purpose of the current study is to determine whether there is a correlation between these imaging techniques and mitotic activity in malignant gliomas.

Procedures

We retrospectively examined 29 patients with recurrent malignant gliomas who underwent structural MRI, diffusion MRI, and [¹⁸F]FDOPA PET prior to surgical resection. Qualitative associations were noted, and quantitative voxel-wise and median measurement correlations between [¹⁸F]FDOPA PET, ADC, and mitotic index were performed.

Results

Areas of high [¹⁸F]FDOPA uptake exhibited low ADC and areas of hyperintensity T2/fluid-attenuated inversion recovery (FLAIR) with low [¹⁸F]FDOPA uptake exhibited high ADC. There was a significant inverse voxel-wise correlation between [¹⁸F]FDOPA and ADC for all patients. Median [¹⁸F]FDOPA uptake and median ADC also showed a significant inverse correlation. Median [¹⁸F]FDOPA uptake was positively correlated, and median ADC was inversely correlated with mitotic index from resected tumor tissue.

Conclusions

A significant association may exist between [¹⁸F]FDOPA uptake, diffusion MRI, and mitotic activity in recurrent malignant gliomas.

DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123CrossRefPubMed

Bode MK, Ruohonen J, Nieminen MT, Pyhtinen J (2006) Potential of diffusion imaging in brain tumors: a review. Acta Radiol 47:585–594CrossRefPubMed

Ellingson BM, Malkin MG, Rand SD et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548CrossRefPubMedCentralPubMed

Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed

Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828–836CrossRefPubMed

Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036CrossRefPubMed

Guo AC, Cummings TJ, Dash RC, Provenzale JM (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224:177–183CrossRefPubMed

Hayashida Y, Hirai T, Morishita S et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425PubMed

Kinoshita M, Hashimoto N, Goto T et al (2008) Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage 43:29–35CrossRefPubMed

10.

Chenevert TL, McKeever PE, Ross BD (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res Off J Am Assoc Cancer Res 3:1457–1466

11.

Ross BD, Moffat BA, Lawrence TS et al (2003) Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2:581–587PubMed

12.

Moffat BA, Hall DE, Stojanovska J et al (2004) Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma 17:249–259CrossRefPubMed

13.

Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMed

14.

Asao C, Korogi Y, Kitajima M et al (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 26:1455–1460PubMed

15.

Sundgren PC, Fan X, Weybright P et al (2006) Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24:1131–1142CrossRefPubMed

16.

Weber WA, Wester HJ, Grosu AL et al (2000) O-(2-[¹⁸F]fluoroethyl)-L-tyrosine and L-[methyl-¹¹C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27:542–549CrossRefPubMed

17.

Becherer A, Karanikas G, Szabo M et al (2003) Brain tumour imaging with PET: a comparison between [¹⁸F]fluorodopa and [¹¹C]methionine. Eur J Nucl Med Mol Imaging 30:1561–1567CrossRefPubMed

18.

Grosu AL, Astner ST, Riedel E et al (2011) An interindividual comparison of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-¹¹C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 81:1049–1058CrossRefPubMed

19.

Isselbacher KJ (1972) Sugar and amino acid transport by cells in culture–differences between normal and malignant cells. N Engl J Med 286:929–933CrossRefPubMed

20.

Busch H, Davis JR, Honig GR et al (1959) The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 19:1030–1039PubMed

21.

Kato T, Shinoda J, Oka N et al (2008) Analysis of ¹¹C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 29:1867–1871CrossRefPubMed

22.

Sato N, Suzuki M, Kuwata N et al (1999) Evaluation of the malignancy of glioma using ¹¹C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22:210–214CrossRefPubMed

23.

Chiang PK, Cantoni GL (1977) Activation of methionine for transmethylation. Purification of the S-adenosylmethionine synthetase of bakers’ yeast and its separation into two forms. J Biol Chem 252:4506–4513PubMed

24.

Meyer GJ, Schober O, Hundeshagen H (1985) Uptake of ¹¹C-L- and D-methionine in brain tumors. Eur J Nucl Med 10:373–376PubMed

25.

Souba WW (1993) Glutamine and cancer. Ann Surg 218:715–728CrossRefPubMedCentralPubMed

26.

Yamada Y, Uchida Y, Tatsumi K et al (1998) Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 39:1160–1166PubMed

27.

Floeth FW, Pauleit D, Sabel M et al (2006) ¹⁸F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47:776–782PubMed

28.

Fueger BJ, Czernin J, Cloughesy T et al (2010) Correlation of 6-¹⁸F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 51:1532–1538CrossRefPubMed

29.

Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046–2053CrossRefPubMed

30.

Nuyts J, Michel C, Dupont P (2001) Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging 20:365–375CrossRefPubMed

31.

Chen W, Silverman DH, Delaloye S et al (2006) ¹⁸F-FDOPA PET imaging of brain tumors: comparison study with ¹⁸F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

32.

Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res POR 12:143–147CrossRef

33.

Prayson RA (2005) The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 12:144–148CrossRefPubMed

34.

Hatakeyama T, Kawai N, Nishiyama Y et al (2008) ¹¹C-methionine (MET) and ¹⁸F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009–2017CrossRefPubMed

35.

Huang MC, Shih YH, Chen MH et al (2005) Malignancy of intracerebral lesions evaluated with ¹¹C-methionine-PET. J Clin Neurosci Off J Neurosurg Soc Australas 12:775–780

36.

Kim S, Chung JK, Im SH et al (2005) ¹¹C-methionine PET as a prognostic marker in patients with glioma: comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 32:52–59CrossRefPubMed

37.

Yuan W, Holland SK, Jones BV et al (2008) Characterization of abnormal diffusion properties of supratentorial brain tumors: a preliminary diffusion tensor imaging study. J Neurosurg Pediatr 1:263–269CrossRefPubMed

38.

Gauvain KM, McKinstry RC, Mukherjee P et al (2001) Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 177:449–454CrossRefPubMed

Title: Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas
Authors: Elena Karavaeva
Robert J. Harris
Kevin Leu
Maryam Shabihkhani
William H. Yong
Whitney B. Pope
Albert Lai
Phioanh L. Nghiemphu
Linda M. Liau
Wei Chen
Johannes Czernin
Timothy F. Cloughesy
Benjamin M. Ellingson
Publication date: 01-06-2015
Publisher: Springer US
Published in: Molecular Imaging and Biology / Issue 3/2015
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-014-0807-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship Between [¹⁸F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2015

World Molecular Imaging Congress 2015: Precision Medicine Visualized

BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study)

[99mTc]Annexin V-128 SPECT Monitoring of Splenic and Disseminated Listeriosis in Mice: a Model of Imaging Sepsis

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

[18F]Fluoromethylcholine as a Chemotherapy Response Read-Out in Prostate Cancer Cells

Characterization and Evaluation of the Artemis Camera for Fluorescence-Guided Cancer Surgery